Gut microbiota interactions with anti-diabetic medications and pathogenesis of type 2 diabetes mellitus.

Kant, Ravi; Chandra, Lakshya; Verma, Vipin; Nain, Priyanshu; Bello, Diego; Patel, Siddharth; Ala, Subash; Chandra, Rashmi; Antony, Mc Anto

Kant, Ravi; Chandra, Lakshya; Verma, Vipin; Nain, Priyanshu; Bello, Diego; Patel, Siddharth; Ala, Subash; Chandra, Rashmi; Antony, Mc Anto.

Afiliação

Kant R; Department of Endocrinology, Diabetes and Metabolism, Medical University of South Carolina, Anderson, SC 29621, United States.
Chandra L; Department of Endocrinology, Diabetes and Metabolism, AnMed Health, Anderson, SC 29621, United States. kant.ravi.md@gmail.com.
Verma V; Department of Internal Medicine, St Francis Hospital, Greenville, SC 29601, United States.
Nain P; Department of Internal Medicine, Medical University of South Carolina, Anderson, SC 29621, United States.
Bello D; Department of Internal Medicine, AnMed Health, Anderson, SC 29621, United States.
Patel S; Department of Graduate Medical Education, Maulana Azad Medical College, Delhi 110002, India.
Ala S; Department of Surgery, AnMed Health, Anderson, SC 29621, United States.
Chandra R; Department of Internal Medicine, Decatur Morgan Hospital, Decatur, AL 35601, United States.
Antony MA; Department of Internal Medicine, St Francis Hospital, Greenville, SC 29601, United States.

World J Methodol ; 12(4): 246-257, 2022 Jul 20.

Article em En | MEDLINE | ID: mdl-36159100

Palavras-chave

Cardiovascular disease; Dysbiosis; Gut microbiota; Metabolic disease; Short chain fatty acid; Trimethylamine-N-oxide

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies Idioma: En Revista: World J Methodol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google